LobbyingGenbiopro lobbying by quarter
Genbiopro's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $35K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Pharmacy.
Genbiopro
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $35K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $40K | 1 |
| Q1 2023 | $35K | 1 |
| Q2 2023 | $35K | 1 |
| Q3 2023 | $35K | 1 |
| Q4 2023 | $35K | 1 |
| Q1 2024 | $35K | 1 |
| Q2 2024 | $35K | 1 |
| Q3 2024 | $35K | 1 |
| Q4 2024 | $35K | 1 |
| Q1 2025 | $35K | 1 |
| Q2 2025 | $35K | 1 |
| Q3 2025 | $35K | 1 |
| Q4 2025 | $35K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$153.3K · 15 reports
- Pharmacy$153.3K · 15 reports
- Veterans$153.3K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Food & Drug Administration (FDA)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Emergent Strategies | $460K | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Emergent Strategies | Under $5,000 |
| 04/20for Q1 | Emergent Strategies | Under $5,000 |
| 01/20for Q4 2025 | Emergent Strategies | $35K |
| 25/10/20for Q3 2025 | Emergent Strategies | $35K |
| 25/07/21for Q2 2025 | Emergent Strategies | $35K |
| 25/04/21for Q1 2025 | Emergent Strategies | $35K |
| 25/01/21for Q4 2024 | Emergent Strategies | $35K |
| 24/10/21for Q3 2024 | Emergent Strategies | $35K |
| 24/07/19for Q2 2024 | Emergent Strategies | $35K |
| 24/04/09for Q1 2024 | Emergent Strategies | $35K |
| 24/01/19for Q4 2023 | Emergent Strategies | $35K |
| 23/10/16for Q3 2023 | Emergent Strategies | $35K |
| 23/07/05for Q2 2023 | Emergent Strategies | $35K |
| 23/04/17for Q1 2023 | Emergent Strategies | $35K |
| 23/01/20for Q4 2022 | Emergent Strategies | $40K |